|
|
||||||||






* Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, University Hospital (Centre Hospitalier Universitaire Vaudois), Lausanne, Switzerland;
Ludwig Institute Clinical Trial Center, Division of Medical Oncology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032; and
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland
The CD8 coreceptor plays a crucial role in both T cell development in the thymus and in the activation of mature T cells in response to Ag-specific stimulation. In this study we used soluble peptides-MHC class I (pMHC) multimeric complexes bearing mutations in the CD8 binding site that impair their binding to the MHC, together with altered peptide ligands, to assess the impact of CD8 on pMHC binding to the TCR. Our data support a model in which CD8 promotes the binding of TCR to pMHC. However, once the pMHC/TCR complex is formed, the TCR dominates the pMHC/TCR dissociation rates. As a consequence of these molecular interactions, under physiologic conditions CD8 plays a key role in complex formation, resulting in the enhancement of CD8 T cell functions whose specificity, however, is determined by the TCR.
This article has been cited by other articles:
![]() |
A. S. Chervin, J. D. Stone, P. D. Holler, A. Bai, J. Chen, H. N. Eisen, and D. M. Kranz The Impact of TCR-Binding Properties and Antigen Presentation Format on T Cell Responsiveness J. Immunol., July 15, 2009; 183(2): 1166 - 1178. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wooldridge, H. A. van den Berg, M. Glick, E. Gostick, B. Laugel, S. L. Hutchinson, A. Milicic, J. M. Brenchley, D. C. Douek, D. A. Price, et al. Interaction between the CD8 Coreceptor and Major Histocompatibility Complex Class I Stabilizes T Cell Receptor-Antigen Complexes at the Cell Surface J. Biol. Chem., July 29, 2005; 280(30): 27491 - 27501. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. O. Holman, E. R. Walsh, and S. C. Jameson Characterizing the Impact of CD8 Antibodies on Class I MHC Multimer Binding J. Immunol., April 1, 2005; 174(7): 3986 - 3991. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Mayr, D. Bund, M. Schlee, A. Moosmann, D. M. Kofler, M. Hallek, and C.-M. Wendtner Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes Blood, February 15, 2005; 105(4): 1566 - 1573. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M.-L. Choi, J.-L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I. F. Hermans, J. D. Silk, F. Mirza, M. J. Palmowski, et al. High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining J. Immunol., November 15, 2003; 171(10): 5116 - 5123. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |